Country or Global license
Contact David Cunningham,
Account Manager,
781-972-5472
cunningham@healthtech.com

Length 
232 pages 

Date published 
November 2007 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Add to Del.icio.us Add to furl Add to digg Add to Connotea EMail Page Printer Friendly Book Mark

Overview

Molecular Diagnostics: A Rapidly Shifting Commercial and Technology Landscape

By Lucy Sannes, PhD, MBA

Molecular diagnostic tests are now used for a wide range of applications, including:

  • Human clinical molecular diagnostic testing
  • Veterinary molecular diagnostic testing
  • Identity testing
  • Forensic testing
  • Histocompatibility testing

Within these broad disease areas, molecular diagnostics tests have a wide range of applications, including:

  • Identification of individuals who are at increased risk of developing certain disorders
  • Screening apparently healthy populations
  • Diagnosis
  • Determining prognosis, such as with cancer
  • Personalized medicine applications, including pharmacogenetic tests such as drug metabolism tests to avoid adverse drug effects and companion diagnostics to identify patients who will respond to a specific drug
  • Monitoring response to therapy

Molecular Diagnostics: A Rapidly Shifting Commercial and Technology Landscape focuses on human clinical molecular diagnostics. Even within this field, molecular diagnostics is being applied to a wide range of diseases and applications. The first molecular diagnostics tests to reach the market were for infectious diseases, and this remains the largest segment of the molecular diagnostics market. Molecular oncology tests have been emerging as a second significant—and rapidly growing—market segment. Molecular diagnostics is also starting to emerge as an important tool for inherited disorders, cardiovascular disorders, and other disease areas.

This report provides a thorough discussion of the many companies involved in molecular diagnostics and their commercial products either on the market or in development for these applications. Molecular diagnostics has emerged as a significant segment of the overall clinical diagnostics market. Overall, the molecular diagnostics market is growing rapidly, although some segments are growing more rapidly than others. This report provides an overview of the molecular diagnostics market, and discusses many of the trends in this market—including factors that are driving the growth.

This report also includes results from a Web survey of individuals involved in molecular diagnostics research, development, and use. More than 250 people responded to the survey, pointing out in a question what they think will be the biggest growth areas over the next 5 years:

Figure 7A. Growth Areas Next 5 Years

Question 7. What do you believe is the most promising major application area for molecular diagnostic testing over the next 5 years?

Overview

Source: CHI Molecular Diagnostics Survey – July 2007

As molecular diagnostics moves into the future, companies in this market will face a number of challenges. Selected examples of the challenges are discussed. The molecular diagnostics market is changing rapidly and is becoming highly competitive. The market shows considerable promise for new tests to improve the diagnosis and treatment of a wide range of diseases and disorders.

About the Author:

Lucy J. Sannes, PhD, MBA, is president of Sannes & Associates, a consulting firm specializing in evaluation and management of the biosciences. Before forming Sannes & Associates, she held management positions at Genetic Systems and Abbott Laboratories in product development, product support, and technical marketing. Dr. Sannes received her PhD in biological chemistry from the University of Michigan and her MBA from Seattle Pacific University.
 



"CHI's Insight Pharma Reports are a cost-effective and reliable source of information about the markets we serve. The cost for us to conduct this kind of business research on our own would be prohibitive. CHI's Insight Pharma Reports allow us to keep on top of developments in this rapidly moving field."

--Donald N. Halbert, ph.D., EVP of R&D, Iconix Biosciences